SCHEMBL6366163

SCHEMBL6366163

CC(C)c1n[nH]c2c(=O)[nH]c(Cc3c(Cl)cccc3Cl)nc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE9A O76083 4/20 0.48
▸ PDE1A P54750 4/20 0.48
▸ PDE1B Q01064 4/20 0.48
▸ PDE1C Q14123 4/20 0.48
▸ PDE5A O76074 2/20 0.48
▸ LCK P06239 1/20 0.45
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ AR P10275 1/20 0.40
▸ CCNK O75909 1/20 0.38
▸ CCND3 P30281 1/20 0.38
▸ GSK3B P49841 1/20 0.38
▸ CDK7 P50613 1/20 0.38
▸ CDK9 P50750 1/20 0.38
▸ CCNH P51946 1/20 0.38
▸ CDK6 Q00534 1/20 0.38
▸ CDK12 Q9NYV4 1/20 0.38
▸ LMNA P02545 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6365921 0.93 PDE9A (0.47) PDE9APDE1APDE1BPDE1CPDE5A
SCHEMBL6366350 0.92 PDE9A (0.44) PDE9APDE1APDE1BPDE1CPDE5A
SCHEMBL6365815 0.89 PDE9A (0.43) PDE9APDE1APDE1BPDE1CPDE5A
SCHEMBL6371757 0.86 PDE9A (0.43) PDE9APDE1APDE1BPDE1CPDE5A
SCHEMBL6367456 0.84 AR (0.43) PDE9APDE1APDE1BPDE1CPDE5A
SCHEMBL3494823 0.83 PDE5A (0.71) PDE9APDE1APDE1BPDE1CPDE5A
SCHEMBL6367562 0.82 PDE9A (0.52) PDE9APDE1APDE1BPDE1CPDE5A
SCHEMBL6366055 0.81 PDE9A (0.51) PDE9APDE1APDE1BPDE1CPDE5A
SCHEMBL6365512 0.81 PDE9A (0.52) PDE9APDE1APDE1BPDE1CPDE5A
SCHEMBL6367635 0.81 HTT (0.41) PDE9APDE1APDE1BPDE1CPDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6967204-B2 Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors PFIZER INC (US) 2005-11-22 — — US disclosed
US-20050070557-A1 Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors PFIZER INC 2005-03-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070557-A1 Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors GPR119, PDE2A, PDE9A PDE9A 3/4885PDE1A 46/4885PDE1B 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback